Clinical Trials
39 trialsTINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Yale University
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
Fox Chase Cancer Center
SAHA
Columbia University
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
M.D. Anderson Cancer Center
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
M.D. Anderson Cancer Center
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
University of Washington
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
Vorinostat in Children
National Center for Tumor Diseases, Heidelberg
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Masonic Cancer Center, University of Minnesota
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
OHSU Knight Cancer Institute
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Stanford University
COMBOSTAT
The Methodist Hospital Research Institute
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
Weill Medical College of Cornell University
ZOLINZA
Samsung Medical Center
VEIL
Peter MacCallum Cancer Centre, Australia
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
University of Rochester
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Ohio State University Comprehensive Cancer Center
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Memorial Sloan Kettering Cancer Center
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
City of Hope Medical Center
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
City of Hope Medical Center